Coherus Q2 Revenue Rises 40% but Misses Estimates; Wider Loss and Clinical Catalysts Ahead
CHRS sits 74% above its 52-week low of $0.81.
Summary
Coherus reported Q2 revenue of $14.31M, up 40% year-over-year driven by LOQTORZI volume, but slightly below the $14.40M consensus. Adjusted net loss of $30.14M was significantly wider than the expected $25.40M, reflecting higher operating costs. The company highlighted strong demand with record new patient starts and improved therapy duration. Looking ahead, multiple clinical data readouts are expected in the second half of 2026, with mature datasets in October and a new Phase 1b prostate cancer trial starting in the fall. The revenue miss and wider loss may pressure the stock, but the upcoming catalysts could shift sentiment if positive.
At the time of this announcement, CHRS was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $223.7M. The 52-week trading range was $0.81 to $2.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.